Kids with a rare bone cancer might live longer if prescribed a drug that blocks blood supply to tumors, researchers say.
The drug pazopanib (Votrient) extended the lives of a small group of kids with Ewing sarcoma, which causes cancerous tumors in their bones, researchers report in the journal Frontiers in Oncology.
"While we wait for new treatment options, it is possible to implement this existing drug to improve outcomes in very high-risk patients," lead researcher Anna Raciborska, head of oncology at Poland's Warsaw Mother and Child Institute, said in a news release. "It opens the door to targeted therapies earlier in the disease course, potentially improving survival and quality of life."
Typically, fewer than a quarter of children with advanced Ewing sarcoma survive five years after their diagnosis, researchers said in background notes.
Related
